We have located links that may give you full text access.
Early Onset Acute Coronary Artery Occlusion After Pembrolizumab in Advanced Non-Small Cell Lung Cancer: A Case Report.
Cardiovascular Toxicology 2021 May 28
Myocarditis, arrhythmia, and cardiomyopathy are the most reported acute cardiotoxicities in cancer patients receiving immune checkpoint inhibitor (ICI) therapy. But it is not clear whether ICI can cause acute coronary occlusive disease. We reported acute coronary artery occlusion in an 83-year-old male non-small cell lung cancer (NSCLC) patient after 2 days of pembrolizumab infusion. This patient had a server-underlying three-vessel coronary artery disease without symptoms. The patient was discharged from the hospital two weeks after percutaneous coronary intervention. Pembrolizumab may cause destabilization of severely stenosed atherosclerotic plaques, which contributes to acute myocardial infarction. We should take more caution about lung cancer patients with baseline coronary disease when treat with ICI. CRP may be a useful predictor factor of early-onset coronary events in these patients.
Full text links
Related Resources
Trending Papers
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app